Prospect: information for the patient
Parnido3 mg prolonged-release EFG tablets
Parnido6 mg prolonged-release EFG tablets
Parnido9 mg prolonged-release EFG tablets
paliperidone
Read this prospect carefully before starting to take this medicine, as it contains important information for you.
-Keep this prospect, as you may need to read it again.
-If you have any questions, consult your doctor or pharmacist.
-This medicine has been prescribed only for you, and you should not give it to other people even if they have the same symptoms as you, as it may harm them.
1.What is Parnido and what it is used for.
2.What you need to know before starting to take Parnido
3.How to take Parnido
4.Possible adverse effects
5.Storage of Parnido
6.Contents of the package and additional information.
Paliperidonecontineelprincipioactivopaliperidonaquepertenecealaclasedemedicamentosantipsicóticos.
Paliperidoneseusaparatratarlaesquizofreniaenadultosyadolescentesde15añosdeedadenadelante.
Laesquizofreniaesuntrastornoqueprovocasíntomasqueconsistenenoír,verosentircosasquenoexisten,tenercreenciaserróneas,tenerunadesconfianzafueradelonormal,encerrarseensimismo,hablaincoherenteyaplanamientodelaconductaylaemotividad.Laspersonasquepadecenestetrastornotambiénsepuedensentirdeprimidas,ansiosas,culpablesotensas.
Paliperidoneseusatambiénparatratareltrastornoesquizoafectivoenadultos.
Eltrastornoesquizoafectivoesunaafecciónmentalporlaquelapersonaexperimentavariosdelossíntomasdelaesquizofrenia(enumeradosenelpárrafoanterior)ademasdesíntomasdetrastornodelanimo(sensacióndeeuforia,detristeza,deagitación,estadodistraido,insomnio,verborrea,pérdidadeinteresenactividadescotidianas,suenoexcesivooescaso,ingestiónexcesivaoescasadealimentosypensamientosrecurrentesdesuicidio).
Paliperidonepuedeayudaraaliviarlossíntomasdesuenfermedadyevitarquereaparezcan.
Do not takepaliperidone
-if you are allergic to paliperidone, risperidone, or any of the other ingredients in thismedicine(listed in section6)
Warnings andprecautions
Consult your doctor or pharmacist before starting to take paliperidone..
If you have any of these conditions, please consult your doctor as it may benecesarioan adjustment of your dose or to keep you under observation for atiempo.
Because in very rare cases, a dangerously low number of a type of white blood cells necessary to fight infections in the blood has been observed in patients treated with paliperidone, your doctor may check the number of whiteblancas.
Paliperidone may cause you to gain weight. Significant weight gain can negatively affect your health. Your doctor will regularly monitor your weight.
In patients treated with paliperidone, diabetes mellitus or worsening of pre-existing diabetes mellitus has been observed. Your doctor should check for signs of increased blood sugar.Inpatients with pre-existing diabetes mellitus, blood sugar should be regularly monitored.
During cataract surgery, the pupil (the small circle located in the middle of the eye) may not dilate as needed. Additionally, the iris (the colored part of the eye) may become flaccid during surgery and this may cause damage to the eye.Siyou are planning to have eye surgery, be sure to inform your ophthalmologist thatestáusando estemedicamento.
Children andadolescents
Paliperidone should not be administered to children and adolescents under 15 years of age for the treatment ofschizophrenia.
Paliperidone should not be administered to children and adolescents under 18 years of age for the treatment of schizoaffective disorder.
This is because it is unknown whether paliperidone is safe or effective in this age group.
Other medications and paliperidone
Inform your doctor or pharmacist if you are using, have used recently, or may need to use any other medication.
Abnormalities in heart function may occur when this medication is taken with other medications for heart rhythm control or other medications such as antihistamines, antimalarials, orantipsicóticos.
Since this medication primarily acts on the brain, this medication may interfere with other medications (or alcohol) that also act on it, due to the sum of effects onthefunctioncerebral.
This medication may reduce blood pressure, so you should be careful if you take this medication with other medications that alsoreduzcanbloodarterial.
This medication may reduce the effect of medications for Parkinson's disease and restless legs syndrome (e.g.,levodopa).
The effects of this medication may be affected if you take medications that influence the speed of intestinalmovements(e.g.,metoclopramida).
Reduction of this medication dose should be considered when administered withvalproato.
It is not recommended to use oral risperidone with this medication as thiscombinaciónmaycause an increase in adverseadversos.
Parnido should be used with caution with medications that increase the activity of the central nervous system (psychoestimulants such as metilphenidato).
Paliperidone withalcohol
You should avoid consuming alcohol during treatment with thismedicamento.
Pregnancy andlactation
If you are pregnant or breastfeeding, or if you think you may be pregnant or plan to become pregnant, consult your doctor or pharmacist before using thismedicamento.
You should not take this medication during pregnancy unless you have discussed it with yourmédico.
The following symptoms may occur in newborn babies, from mothers who have been treated with paliperidone in the last trimester of pregnancy (last three months of your pregnancy):temblor,rigidez and/or weakness, somnolence, agitation, breathing problems, and difficulty feeding. If your baby develops any of these symptoms, you should contact yourmédico.
You should not breastfeed your baby while taking this medication.
Driving and use ofmachinery
During treatment with this medication, dizziness and vision problems (see section 4, possible adverse effects) may occur. This should be taken into account when requiring maximum attention, for example, when driving or operatingmaquinaria.
Paliperidone contains sodium
This medication contains less than 23 mg of sodium (1 mmol) per tablet; this is, essentially “sodium-free”.
Follow exactly the administration instructions of this medication indicated by your doctor or pharmacist. In case of doubt, consult your doctor or pharmacist again.
Use in adults
The recommended dose in adults is 6 mg once a day in the morning. Your doctor may increase or decrease it within the dosing interval of 3 mg to 12 mg once a day in case of schizophrenia or 6 mg to 12 mg once a day in case of schizoaffective disorder. This depends on how well the medication works for you.
Use in adolescents and children
The recommended starting dose for the treatment of schizophrenia in adolescents aged 15 years or older is 3 mg once a day taken in the morning.
For adolescents weighing 51 kg or more, the dose can be increased within the interval of 6 mg to 12 mg once a day.
For adolescents weighing less than 51 kg, the dose can be increased to 6 mg once a day.
Your doctor will decide how much to administer to you. The amount you take depends on how well the medication works for you.
How and when to take paliperidone
This medication should be taken by mouth, swallowed whole with water or other liquids. It cannot be chewed, broken, or crushed.
This medication should be taken in the mornings with breakfast or on an empty stomach, but in the same way every day. Do not alternate between taking the medication with breakfast and on an empty stomach the next day.
The active ingredient, paliperidone, dissolves once swallowed, and the coating of the tablet is eliminated from the body by the kidneys.
Patients with kidney problems
Your doctor may adjust the dose of this medication according to your kidney function.
Patients of advanced age
Your doctor may reduce your medication dose if your kidney function is reduced.
If you take more paliperidone than you should
In case of overdose or accidental ingestion, consult your doctor, pharmacist, or go to the nearest hospital immediately, or call the Toxicological Information Service. Phone: 91 562 04 20 indicating the medication and the amount ingested. You may experience drowsiness, confusion, abnormal body movements, difficulty staying upright and walking, dizziness due to reduced blood pressure, and alterations in heartbeats.
If you forgot to take paliperidone
Do not take a double dose to compensate for the missed doses. If you forget a dose, take the next dose the next day. If you forget two or more doses, contact your doctor.
If you interrupt the treatment with paliperidone
Do not stop taking this medication as you will lose the effects of the medication. Do not stop taking this medication unless your doctor tells you to, as the symptoms may reappear.
If you have any other doubts about the use of this medication, ask your doctor or nurse.
Like all medicines, this medicine can cause side effects, althoughnotall people experience them.
Inform your doctor immediately if you experience any of the following:
Very common side effects: may affect more than 1 in 10 patients:
Common side effects: may affect up to 1 in 10 patients:
Rare side effects: may affect up to 1 in 1,000 patients:
Unknown: their frequency cannot be estimated from the available data:
The following side effects have appeared with the use of another medication called risperidone, which is very similar to paliperidone, so it is also expected to appear with paliperidone: eating disorder related to sleep, other types of blood vessel problems in the brain, crackling sounds in the lungs, and severe or life-threatening skin rash with blisters and peeling of the skin that can start in the mouth, nose, eyes, and genitals and spread to other parts of the body (Stevens-Johnson syndrome/toxic epidermal necrolysis). Other eye problems may also occur during cataract surgery. During cataract surgery, a condition called intraoperative floppy iris syndrome (IFIS) may occur if you are taking or have taken paliperidone. If you need to undergo cataract surgery, make sure to inform your ophthalmologist if you are taking or have taken this medication.
Additional side effects in adolescents:
Adolescents generally experienced side effects similar to those found in adults, except for the following side effects that were detected more frequently:
Reporting side effects:
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this prospectus. You can also report them directly through the Spanish System for Pharmacovigilance of Medicines for Human Use:https://www.notificaram.es.By reporting side effects, you can contribute to providing more information on the safety of this medication.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the packaging after CAD. The expiration date is the last day of the month indicated.
Store in the original packaging to protect it from moisture.
Medicines should not be disposed of through drains or trash. Deposit the containers and medicines you no longer need at the SIGRE collection point at the pharmacy. Ask your pharmacist how to dispose of the containers and medicines you no longer need. By doing so, you will help protect the environment.
Each prolonged-release tablet contains 3 mg, 6 mg or 9 mg of paliperidone.
-The other components are:
Core: macrogol 200 000, macrogol 7 000 000, macrogol 4 000, hydroxybutyltoluene, povidone, sodium chloride, microcrystalline cellulose, magnesium stearate, red iron oxide (E172), hydroxypropylcellulose and cellulose acetate.
Covering: hypromellose, titanium dioxide (E171), talc, propylene glycol, yellow iron oxide (E172) – only for 6 mg tablets and red iron oxide (E172) – only for 9 mg tablets.
Printed ink: shellac, black iron oxide (E172) and propylene glycol. See section 2 “Parnido contains sodium”.
Appearance of the product and contents of the pack
3 mg: Coated tablets, biconvex, round, white to light grey in color with a possible irregular surface and printed with the mark P3 on one side of the tablet. Diameter: approximately 9 mm.
6 mg: Coated tablets, biconvex, round, yellowish-brown in color with a possible irregular surface and printed with the mark P6 on one side of the tablet. Diameter: approximately 9 mm.
9 mg: Coated tablets, biconvex, round, light pink in color with a possible irregular surface and printed with the mark P9 on one side of the tablet. Diameter: approximately 9 mm.
Parnido is available in packs of 28, 30, 56, 60, 84, 90 or 98 prolonged-release tablets in blisters.
Only some pack sizes may be marketed.
Marketing Authorization Holder
TAD Pharma GmbH, Heinz-Lohmann-Straße 5, 27472 Cuxhaven, Germany
Responsible Person for Manufacturing
KRKA d.d. Novo mesto, Smarjeska cesta 6, 8501 Novo mesto, Slovenia
You can obtain more information about this medicinal product by contacting the local representative of the marketing authorization holder:
KRKA Farmacéutica, S.L., C/ Anabel Segura 10, 28108 Alcobendas, Madrid, Spain
This medicinal product is authorized in the Member States of the European Economic Area with the following names:
Member State | Medicinal Product Name |
Hungary | Paliperidon Krka 3 mg retard tabletta Paliperidon Krka 6 mg retard tabletta Paliperidon Krka 9 mg retard tabletta |
Belgium | ???????3 mg?????????????????????????????? ???????6 mg?????????????????????????????? ???????9 mg?????????????????????????????? |
Czech Republic | Parnido |
Estonia | Parnido |
Spain | Parnido3 mg prolonged-release tablets EFG Parnido6 mg prolonged-release tablets EFG Parnido9 mg prolonged-release tablets EFG |
Croatia | Parnido3 mgtablete s produljenim oslobadanjem Parnido6 mgtablete s produljenim oslobadanjem Parnido9 mg tablete s produljenim oslobadanjemy |
Ireland | Parnido 3 mg prolonged-release tablets Parnido 6 mg prolonged-release tablets Parnido 9 mg prolonged-release tablets |
Lithuania | Parnido3 mgpailginto atpalaidavimo tabletes Parnido6 mgpailginto atpalaidavimo tabletes Parnido 9 mgpailginto atpalaidavimo tabletes |
Latvia | Parnido 3 mg ilgstošas darbibas tabletes Parnido 6 mg ilgstošas darbibas tabletes Parnido 9 mg ilgstošas darbibas tabletes |
Portugal | Parnido |
Romania | Parnido3 mg comprimate cu eliberare prelungita Parnido6 mg comprimate cu eliberare prelungita Parnido9 mg comprimate cu eliberare prelungita |
Slovenia | Parnido3 mg tablete s podaljšanim sprošcanjem Parnido6 mg tablete s podaljšanim sprošcanjem Parnido9 mg tablete s podaljšanim sprošcanjem |
Slovakia | Parnido3 mgtablety s predlženým uvolnovaním Parnido6 mgtablety s predlženým uvolnovaním Parnido9 mgtablety s predlženým uvolnovaním |
Last revision date of this leaflet: April 2024
Further information on this medicinal product is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS)http://www.aemps.gob.es/
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.